These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33201837)

  • 1. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
    Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
    Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
    Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
    Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop.
    Jiang Z; Yang G; Wang G; Wan J; Zhang Y; Song W; Zhang H; Ni J; Zhang H; Luo M; Wang K; Peng B
    J Exp Clin Cancer Res; 2024 Oct; 43(1):288. PubMed ID: 39425205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
    Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
    Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
    [No Abstract]   [Full Text] [Related]  

  • 9. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
    Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
    Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
    Wu S; Wang Y
    Altern Ther Health Med; 2024 Jul; 30(7):268-273. PubMed ID: 37971460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
    Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
    BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nesprin1 Deficiency Is Associated with Poor Prognosis of Renal Cell Carcinoma and Resistance to Sunitinib Treatment.
    Fukushima T; Kobatake K; Miura K; Takemoto K; Yamanaka R; Tasaka R; Kohada Y; Miyamoto S; Sekino Y; Kitano H; Goto K; Ikeda K; Goriki A; Hieda K; Kaminuma O; Hinata N
    Oncology; 2024; 102(10):868-879. PubMed ID: 38442705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
    Zhu L; Ding R; Yan H; Zhang J; Lin Z
    Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma.
    Makhov P; Sohn JA; Serebriiskii IG; Fazliyeva R; Khazak V; Boumber Y; Uzzo RG; Kolenko VM
    Br J Cancer; 2020 Dec; 123(12):1749-1756. PubMed ID: 32968206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
    Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
    Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
    Dufies M; Nollet M; Ambrosetti D; Traboulsi W; Viotti J; Borchiellini D; Grépin R; Parola J; Giuliano S; Helley-Russick D; Bensalah K; Ravaud A; Bernhard JC; Schiappa R; Bardin N; Dignat-George F; Rioux-Leclercq N; Oudard S; Négrier S; Ferrero JM; Chamorey E; Blot-Chabaud M; Pagès G
    Theranostics; 2018; 8(9):2447-2458. PubMed ID: 29721091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
    Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
    J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
    Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
    Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.